[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fIKP5G26R-6ZD-wgNZSBgjPcIEPYfFrzwmBDVQJa94ys":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":47,"rows":54},"Royal Brompton & Harefield NHS Foundation Trust",[4],139,false,19,9,50680,3,120,[14,17,20,23,26,29,31,33],{"name":15,"count":16},"Cystic Fibrosis",13,{"name":18,"count":19},"Heart Failure",12,{"name":21,"count":22},"Idiopathic Pulmonary Fibrosis",10,{"name":24,"count":25},"Chronic Obstructive Pulmonary Disease",6,{"name":27,"count":28},"Persistent Atrial Fibrillation",5,{"name":30,"count":28},"Coronary Artery Disease",{"name":32,"count":28},"Lung Diseases",{"name":34,"count":35},"Pulmonary Disease, Chronic Obstructive",4,[37,42],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT07498842","Corticosteroid Tapering in Sarcoidosis","2027-06-28","Standard prednisolone taper",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT07402434","A Prospective Study of Advanced Diagnostics in People With an Unclear Diagnosis of Cystic Fibrosis","2028-06-01","Blood test for CFTR Genotyping",[48,49,50,51,52,53],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[55,81,99,123,152,170,198,216,242,270,295,320,344,367,393,420,438,464,482,504,528,552,579,604,622],{"intervention":41,"totalTrials":56,"cells":57},1,{"EARLY_PHASE1":58,"PHASE1":61,"PHASE2":63,"PHASE3":65,"PHASE4":67,"NA":69},{"trials":59,"activeCount":60},[],0,{"trials":62,"activeCount":60},[],{"trials":64,"activeCount":60},[],{"trials":66,"activeCount":60},[],{"trials":68,"activeCount":60},[],{"trials":70,"activeCount":56,"soonestReadout":40},[71],{"nctId":38,"briefTitle":39,"status":72,"phases":73,"primaryCompletion":40,"completion":74,"start":75,"enrollment":76,"conditions":77,"interventions":79},"RECRUITING",[53],"2027-10-18","2026-03-19",100,[78],"Sarcoidosis",[41,80],"Fast prednisolone taper",{"intervention":80,"totalTrials":56,"cells":82},{"EARLY_PHASE1":83,"PHASE1":85,"PHASE2":87,"PHASE3":89,"PHASE4":91,"NA":93},{"trials":84,"activeCount":60},[],{"trials":86,"activeCount":60},[],{"trials":88,"activeCount":60},[],{"trials":90,"activeCount":60},[],{"trials":92,"activeCount":60},[],{"trials":94,"activeCount":56,"soonestReadout":40},[95],{"nctId":38,"briefTitle":39,"status":72,"phases":96,"primaryCompletion":40,"completion":74,"start":75,"enrollment":76,"conditions":97,"interventions":98},[53],[78],[41,80],{"intervention":46,"totalTrials":56,"cells":100},{"EARLY_PHASE1":101,"PHASE1":103,"PHASE2":105,"PHASE3":107,"PHASE4":109,"NA":111},{"trials":102,"activeCount":60},[],{"trials":104,"activeCount":60},[],{"trials":106,"activeCount":60},[],{"trials":108,"activeCount":60},[],{"trials":110,"activeCount":60},[],{"trials":112,"activeCount":56,"soonestReadout":45},[113],{"nctId":43,"briefTitle":44,"status":114,"phases":115,"primaryCompletion":45,"completion":116,"start":117,"enrollment":118,"conditions":119,"interventions":122},"NOT_YET_RECRUITING",[],"2028-09-01","2026-02-02",80,[120,121],"Cystic Fibrosis (CF)","CFTR-related Disorders",[46],{"intervention":124,"totalTrials":56,"cells":125},"Femoston Conti",{"EARLY_PHASE1":126,"PHASE1":128,"PHASE2":130,"PHASE3":132,"PHASE4":134,"NA":150},{"trials":127,"activeCount":60},[],{"trials":129,"activeCount":60},[],{"trials":131,"activeCount":60},[],{"trials":133,"activeCount":60},[],{"trials":135,"activeCount":60},[136],{"nctId":137,"briefTitle":138,"status":139,"phases":140,"primaryCompletion":141,"completion":142,"start":143,"enrollment":144,"conditions":145,"interventions":148},"NCT02264743","Oral Verses Patch Trial In Menopausal Women - Individualisation of Oestrogen Therapy","UNKNOWN",[52],"2014-11","2015-11","2013-11",60,[146,147],"Venous Thrombosis","Insulin Resistance",[124,149],"EVOREL® CONTI",{"trials":151,"activeCount":60},[],{"intervention":149,"totalTrials":56,"cells":153},{"EARLY_PHASE1":154,"PHASE1":156,"PHASE2":158,"PHASE3":160,"PHASE4":162,"NA":168},{"trials":155,"activeCount":60},[],{"trials":157,"activeCount":60},[],{"trials":159,"activeCount":60},[],{"trials":161,"activeCount":60},[],{"trials":163,"activeCount":60},[164],{"nctId":137,"briefTitle":138,"status":139,"phases":165,"primaryCompletion":141,"completion":142,"start":143,"enrollment":144,"conditions":166,"interventions":167},[52],[146,147],[124,149],{"trials":169,"activeCount":60},[],{"intervention":171,"totalTrials":56,"cells":172},"Prasugrel",{"EARLY_PHASE1":173,"PHASE1":175,"PHASE2":177,"PHASE3":179,"PHASE4":181,"NA":196},{"trials":174,"activeCount":60},[],{"trials":176,"activeCount":60},[],{"trials":178,"activeCount":60},[],{"trials":180,"activeCount":60},[],{"trials":182,"activeCount":60},[183],{"nctId":184,"briefTitle":185,"status":186,"phases":187,"primaryCompletion":188,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":194},"NCT01339026","Evaluating Additional Platelet Inhibition in Patients With High Platelet Reactivity Undergoing Percutaneous Coronary Intervention","TERMINATED",[52],"2013-09","2012-02",44,[192,193],"Cardiovascular Disease","Acute Coronary Syndrome",[171,195],"Plavix",{"trials":197,"activeCount":60},[],{"intervention":195,"totalTrials":56,"cells":199},{"EARLY_PHASE1":200,"PHASE1":202,"PHASE2":204,"PHASE3":206,"PHASE4":208,"NA":214},{"trials":201,"activeCount":60},[],{"trials":203,"activeCount":60},[],{"trials":205,"activeCount":60},[],{"trials":207,"activeCount":60},[],{"trials":209,"activeCount":60},[210],{"nctId":184,"briefTitle":185,"status":186,"phases":211,"primaryCompletion":188,"completion":188,"start":189,"enrollment":190,"conditions":212,"interventions":213},[52],[192,193],[171,195],{"trials":215,"activeCount":60},[],{"intervention":217,"totalTrials":56,"cells":218},"Eplerenone",{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":223,"PHASE3":225,"PHASE4":227,"NA":240},{"trials":220,"activeCount":60},[],{"trials":222,"activeCount":60},[],{"trials":224,"activeCount":60},[],{"trials":226,"activeCount":60},[],{"trials":228,"activeCount":60},[229],{"nctId":230,"briefTitle":231,"status":232,"phases":233,"primaryCompletion":234,"completion":234,"start":235,"enrollment":236,"conditions":237,"interventions":239},"NCT00401856","CMR to Assess Fibrosis in Cardiomyopathy Using Eplerenone","COMPLETED",[52],"2013-04-02","2007-12",42,[238],"Cardiomyopathy",[217],{"trials":241,"activeCount":60},[],{"intervention":243,"totalTrials":56,"cells":244},"Bosentan",{"EARLY_PHASE1":245,"PHASE1":247,"PHASE2":249,"PHASE3":251,"PHASE4":253,"NA":268},{"trials":246,"activeCount":60},[],{"trials":248,"activeCount":60},[],{"trials":250,"activeCount":60},[],{"trials":252,"activeCount":60},[],{"trials":254,"activeCount":60},[255],{"nctId":256,"briefTitle":257,"status":139,"phases":258,"primaryCompletion":259,"completion":260,"start":261,"enrollment":262,"conditions":263,"interventions":267},"NCT00637065","Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study",[52],"2010-04","2010-08","2008-04",48,[264,265,21,266],"Pulmonary Hypertension","Interstitial Lung Disease","Nonspecific Interstitial Pneumonia",[243],{"trials":269,"activeCount":60},[],{"intervention":271,"totalTrials":56,"cells":272},"deferiprone",{"EARLY_PHASE1":273,"PHASE1":275,"PHASE2":277,"PHASE3":279,"PHASE4":281,"NA":293},{"trials":274,"activeCount":60},[],{"trials":276,"activeCount":60},[],{"trials":278,"activeCount":60},[],{"trials":280,"activeCount":60},[],{"trials":282,"activeCount":60},[283],{"nctId":284,"briefTitle":285,"status":139,"phases":286,"completion":287,"start":288,"enrollment":289,"conditions":290,"interventions":292},"NCT00103753","Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major",[52],"2005-06","2004-05",65,[291],"Beta-Thalassemia",[271],{"trials":294,"activeCount":60},[],{"intervention":296,"totalTrials":56,"cells":297},"Ambulatory Oxygen",{"EARLY_PHASE1":298,"PHASE1":300,"PHASE2":302,"PHASE3":304,"PHASE4":306,"NA":318},{"trials":299,"activeCount":60},[],{"trials":301,"activeCount":60},[],{"trials":303,"activeCount":60},[],{"trials":305,"activeCount":60},[],{"trials":307,"activeCount":60},[308],{"nctId":309,"briefTitle":310,"status":232,"phases":311,"primaryCompletion":312,"completion":312,"start":313,"enrollment":314,"conditions":315,"interventions":317},"NCT02286063","Ambulatory Oxygen in Fibrotic Lung Disease (FLD) (AmbOx)",[52],"2018-01-31","2014-08",70,[316],"Lung; Disease, Fibroid (Chronic)",[296],{"trials":319,"activeCount":60},[],{"intervention":321,"totalTrials":56,"cells":322},"Withdrawal of therapy",{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":329,"PHASE4":331,"NA":342},{"trials":324,"activeCount":60},[],{"trials":326,"activeCount":60},[],{"trials":328,"activeCount":60},[],{"trials":330,"activeCount":60},[],{"trials":332,"activeCount":60},[333],{"nctId":334,"briefTitle":335,"status":139,"phases":336,"primaryCompletion":337,"completion":337,"start":338,"enrollment":339,"conditions":340,"interventions":341},"NCT02859311","A Pilot Feasibility Study in Recovered Heart Failure",[52],"2018-08","2016-04",50,[18],[321],{"trials":343,"activeCount":60},[],{"intervention":345,"totalTrials":56,"cells":346},"Morphine Sulfate",{"EARLY_PHASE1":347,"PHASE1":349,"PHASE2":351,"PHASE3":353,"PHASE4":363,"NA":365},{"trials":348,"activeCount":60},[],{"trials":350,"activeCount":60},[],{"trials":352,"activeCount":60},[],{"trials":354,"activeCount":60},[355],{"nctId":356,"briefTitle":357,"status":232,"phases":358,"primaryCompletion":359,"completion":359,"start":360,"enrollment":190,"conditions":361,"interventions":362},"NCT04429516","Morphine Sulfate\u002FPlacebo for the Treatment of PulmonAry Fibrosis Cough",[51],"2023-03-21","2020-12-17",[21],[345],{"trials":364,"activeCount":60},[],{"trials":366,"activeCount":60},[],{"intervention":368,"totalTrials":56,"cells":369},"Rosiglitazone",{"EARLY_PHASE1":370,"PHASE1":372,"PHASE2":374,"PHASE3":376,"PHASE4":389,"NA":391},{"trials":371,"activeCount":60},[],{"trials":373,"activeCount":60},[],{"trials":375,"activeCount":60},[],{"trials":377,"activeCount":60},[378],{"nctId":379,"briefTitle":380,"status":139,"phases":381,"completion":382,"start":383,"enrollment":144,"conditions":384,"interventions":388},"NCT00123227","Rosiglitazone Plaque Study",[51],"2005-05","2002-10",[385,386,387],"Diabetes Mellitus, Type 2","Vascular Diseases","Hypertension",[368],{"trials":390,"activeCount":60},[],{"trials":392,"activeCount":60},[],{"intervention":394,"totalTrials":56,"cells":395},"Rituximab",{"EARLY_PHASE1":396,"PHASE1":398,"PHASE2":400,"PHASE3":402,"PHASE4":416,"NA":418},{"trials":397,"activeCount":60},[],{"trials":399,"activeCount":60},[],{"trials":401,"activeCount":60},[],{"trials":403,"activeCount":60},[404],{"nctId":405,"briefTitle":406,"status":232,"phases":407,"primaryCompletion":408,"completion":408,"start":141,"enrollment":409,"conditions":410,"interventions":414},"NCT01862926","Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD",[50,51],"2021-01",104,[265,411,412,413],"Scleroderma","Idiopathic Inflammatory Myositis","Mixed Connective Tissue Disease",[394,415],"Cyclophosphamide",{"trials":417,"activeCount":60},[],{"trials":419,"activeCount":60},[],{"intervention":415,"totalTrials":56,"cells":421},{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":428,"PHASE4":434,"NA":436},{"trials":423,"activeCount":60},[],{"trials":425,"activeCount":60},[],{"trials":427,"activeCount":60},[],{"trials":429,"activeCount":60},[430],{"nctId":405,"briefTitle":406,"status":232,"phases":431,"primaryCompletion":408,"completion":408,"start":141,"enrollment":409,"conditions":432,"interventions":433},[50,51],[265,411,412,413],[394,415],{"trials":435,"activeCount":60},[],{"trials":437,"activeCount":60},[],{"intervention":439,"totalTrials":56,"cells":440},"Ferric Carboxymaltose",{"EARLY_PHASE1":441,"PHASE1":443,"PHASE2":445,"PHASE3":458,"PHASE4":460,"NA":462},{"trials":442,"activeCount":60},[],{"trials":444,"activeCount":60},[],{"trials":446,"activeCount":60},[447],{"nctId":448,"briefTitle":449,"status":139,"phases":450,"primaryCompletion":451,"completion":452,"start":453,"enrollment":454,"conditions":455,"interventions":456},"NCT03050424","Iron and Chronic Obstructive Pulmonary Disease (COPD) Exercise Trial",[50],"2018-10-01","2019-01-01","2017-04-01",40,[24],[439,457],"Sodium Chloride 0.9%",{"trials":459,"activeCount":60},[],{"trials":461,"activeCount":60},[],{"trials":463,"activeCount":60},[],{"intervention":457,"totalTrials":56,"cells":465},{"EARLY_PHASE1":466,"PHASE1":468,"PHASE2":470,"PHASE3":476,"PHASE4":478,"NA":480},{"trials":467,"activeCount":60},[],{"trials":469,"activeCount":60},[],{"trials":471,"activeCount":60},[472],{"nctId":448,"briefTitle":449,"status":139,"phases":473,"primaryCompletion":451,"completion":452,"start":453,"enrollment":454,"conditions":474,"interventions":475},[50],[24],[439,457],{"trials":477,"activeCount":60},[],{"trials":479,"activeCount":60},[],{"trials":481,"activeCount":60},[],{"intervention":483,"totalTrials":56,"cells":484},"Salbutamol",{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":496,"PHASE3":498,"PHASE4":500,"NA":502},{"trials":486,"activeCount":60},[],{"trials":488,"activeCount":60},[489],{"nctId":490,"briefTitle":491,"status":232,"phases":492,"primaryCompletion":141,"completion":141,"start":493,"enrollment":22,"conditions":494,"interventions":495},"NCT01457261","IPF Drug Deposition Study",[49],"2012-04",[21],[483],{"trials":497,"activeCount":60},[],{"trials":499,"activeCount":60},[],{"trials":501,"activeCount":60},[],{"trials":503,"activeCount":60},[],{"intervention":505,"totalTrials":56,"cells":506},"Beta blocker",{"EARLY_PHASE1":507,"PHASE1":509,"PHASE2":511,"PHASE3":513,"PHASE4":515,"NA":517},{"trials":508,"activeCount":60},[],{"trials":510,"activeCount":60},[],{"trials":512,"activeCount":60},[],{"trials":514,"activeCount":60},[],{"trials":516,"activeCount":60},[],{"trials":518,"activeCount":60},[519],{"nctId":520,"briefTitle":521,"status":139,"phases":522,"primaryCompletion":523,"completion":523,"start":524,"enrollment":525,"conditions":526,"interventions":527},"NCT00832442","Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure",[],"2012-12","2008-08",18240,[18],[505],{"intervention":529,"totalTrials":56,"cells":530},"Fluticasone or placebo",{"EARLY_PHASE1":531,"PHASE1":533,"PHASE2":535,"PHASE3":537,"PHASE4":539,"NA":541},{"trials":532,"activeCount":60},[],{"trials":534,"activeCount":60},[],{"trials":536,"activeCount":60},[],{"trials":538,"activeCount":60},[],{"trials":540,"activeCount":60},[],{"trials":542,"activeCount":60},[543],{"nctId":544,"briefTitle":545,"status":232,"phases":546,"completion":547,"start":548,"enrollment":549,"conditions":550,"interventions":551},"NCT00220259","Cystic Fibrosis Withdrawal of Inhaled Steroids Evaluation Study (CF WISE Study)",[53],"2005-02","2001-05",240,[15],[529],{"intervention":553,"totalTrials":56,"cells":554},"blood drug concentration",{"EARLY_PHASE1":555,"PHASE1":557,"PHASE2":559,"PHASE3":561,"PHASE4":563,"NA":565},{"trials":556,"activeCount":60},[],{"trials":558,"activeCount":60},[],{"trials":560,"activeCount":60},[],{"trials":562,"activeCount":60},[],{"trials":564,"activeCount":60},[],{"trials":566,"activeCount":60},[567],{"nctId":568,"briefTitle":569,"status":139,"phases":570,"primaryCompletion":571,"completion":571,"start":572,"enrollment":573,"conditions":574,"interventions":578},"NCT04674657","Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients",[],"2021-09","2018-09-03",30,[575,576,577],"Critical Illness","Extracorporeal Membrane Oxygenation Complication","Infection",[553],{"intervention":580,"totalTrials":56,"cells":581},"Aminophylline",{"EARLY_PHASE1":582,"PHASE1":584,"PHASE2":586,"PHASE3":588,"PHASE4":590,"NA":592},{"trials":583,"activeCount":60},[],{"trials":585,"activeCount":60},[],{"trials":587,"activeCount":60},[],{"trials":589,"activeCount":60},[],{"trials":591,"activeCount":60},[],{"trials":593,"activeCount":60},[594],{"nctId":595,"briefTitle":596,"status":186,"phases":597,"primaryCompletion":598,"completion":598,"start":599,"enrollment":28,"conditions":600,"interventions":602},"NCT02270827","A Pilot Study Into Health Pre and Post Treatment With Intravenous Aminophylline and Hydrocortisone in Severe Asthmatics",[],"2015-02","2014-06",[601],"Asthma",[580,603],"Hydrocortisone",{"intervention":603,"totalTrials":56,"cells":605},{"EARLY_PHASE1":606,"PHASE1":608,"PHASE2":610,"PHASE3":612,"PHASE4":614,"NA":616},{"trials":607,"activeCount":60},[],{"trials":609,"activeCount":60},[],{"trials":611,"activeCount":60},[],{"trials":613,"activeCount":60},[],{"trials":615,"activeCount":60},[],{"trials":617,"activeCount":60},[618],{"nctId":595,"briefTitle":596,"status":186,"phases":619,"primaryCompletion":598,"completion":598,"start":599,"enrollment":28,"conditions":620,"interventions":621},[],[601],[580,603],{"intervention":623,"totalTrials":56,"cells":624},"Medication to control ventricular rate in AF",{"EARLY_PHASE1":625,"PHASE1":627,"PHASE2":629,"PHASE3":631,"PHASE4":633,"NA":635},{"trials":626,"activeCount":60},[],{"trials":628,"activeCount":60},[],{"trials":630,"activeCount":60},[],{"trials":632,"activeCount":60},[],{"trials":634,"activeCount":60},[],{"trials":636,"activeCount":60},[637],{"nctId":638,"briefTitle":639,"status":232,"phases":640,"primaryCompletion":641,"completion":642,"start":643,"enrollment":644,"conditions":645,"interventions":647},"NCT00878384","Catheter Ablation Versus Medical Rate Control for Atrial Fibrillation in Patients With Heart Failure",[53],"2012-06","2012-07","2009-04",52,[646,18],"Atrial Fibrillation",[623]]